Last reviewed · How we verify
FD-001
At a glance
| Generic name | FD-001 |
|---|---|
| Sponsor | Chengdu FenDi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B Virus (NA)
- A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FD-001 CI brief — competitive landscape report
- FD-001 updates RSS · CI watch RSS
- Chengdu FenDi Pharmaceutical Co., Ltd. portfolio CI